Status:
UNKNOWN
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
Lead Sponsor:
Tanta University
Conditions:
Spontaneous Bacterial Peritonitis
Eligibility:
All Genders
21-65 years
Phase:
PHASE3
Brief Summary
the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.
Detailed Description
due to high recurrence rate of spontaneous bacterial peritonitis , we will study and evaluate the possible efficacy and safety of NTZ as an adjuvant therapy in the secondary prevention of SBP in patie...
Eligibility Criteria
Inclusion
- Patients aged 21 - 65 years old with cirrhosis and ascites who had at least one previous confirmed episode of spontaneous bacterial peritonitis.
Exclusion
- Exclusion criteria included active gastrointestinal bleeding Hepatic encephalopathy (\>grade 2) Hepatocellular carcinoma (HCC) or other malignancies Allergy to used medications.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04746937
Start Date
March 1 2021
End Date
May 1 2022
Last Update
February 10 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.